Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
JAMA Pediatr. 2023 Jan 1;177(1):32-41. doi: 10.1001/jamapediatrics.2022.4581.
Vitamin D deficiency (defined as 25-hydroxyvitamin D [25(OH)D] <20 ng/mL) is prevalent among children living in temperate climates and has been reported to associate independently with stunting, obesity, and early activation of the hypothalamic-pituitary-gonadal axis. Phase 3 randomized clinical trials to investigate the influence of long-term vitamin D replacement on growth, body composition, and pubertal development of school-aged children with vitamin D deficiency are lacking.
To determine whether weekly oral vitamin D supplementation influences linear growth, body composition, or pubertal development in school-aged children living in a setting where vitamin D deficiency is highly prevalent.
DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a double-blind, placebo-controlled randomized clinical trial was conducted from June 2016 to June 2019 at 18 grade schools in Ulaanbaatar, Mongolia. School-aged children (6 to 13 years at baseline) attending participating schools were included. Exclusion criteria included a positive QuantiFERON-TB Gold in-tube assay result, conditions or medications associated with altered vitamin D metabolism, use of vitamin D supplements, signs of rickets, or intention to move from Ulaanbaatar within 4 years. Of 11 475 children invited to participate in the study, 9814 underwent QFT testing, and 8851 with negative results were included in the study. All but 1 participant in the placebo group completed follow-up and were included in the present analysis. Data were analyzed from November 2021 to February 2022.
Weekly oral doses of vitamin D3, 14 000 IU, (n = 4418), or placebo (n = 4433) for 3 years.
Mean z scores for height for age, body mass index for age, and waist-to-height ratio; mean percentage body fat, fat mass, and fat-free mass; and mean Tanner scores for pubertal development.
Of 8851 participants, 4366 (49.3%) were female, and 8165 (92.2%) were of Khalkh ethnicity; the mean (SD) age was 9.4 (1.6) years. A total of 8453 participants (95.5%) were vitamin D deficient at baseline, and mean end-of-study 25(OH)D concentrations among participants randomized to vitamin D vs placebo were 31.0 vs 10.7 ng/mL (mean difference, 20.3; 95% CI; 19.9-20.6). However, vitamin D supplementation did not influence mean height for age, body mass index for age, waist-to-height ratio, percentage body fat, fat mass, fat-free mass, or Tanner scores, either overall or within subgroups defined by baseline 25(OH)D concentration less than 10 ng/mL vs 10 ng/mL or greater, estimated calcium intake less than 500 mg/d vs 500 mg/d or greater, or male vs female sex.
In school-aged children in this study with low baseline vitamin D status, oral vitamin D3 supplementation at a dose of 14 000 IU per week for 3 years was effective in elevating 25(OH)D concentrations but did not influence growth, body composition, or pubertal development.
ClinicalTrials.gov Identifier: NCT02276755.
在居住在温带气候的儿童中,维生素 D 缺乏症(定义为 25-羟维生素 D [25(OH)D] <20ng/mL)很常见,并且据报道与生长迟缓、肥胖和下丘脑-垂体-性腺轴的早期激活独立相关。缺乏针对维生素 D 缺乏的学龄儿童进行长期维生素 D 替代治疗对生长、身体成分和青春期发育影响的 3 期随机临床试验。
确定每周口服维生素 D 补充剂是否会影响生活在维生素 D 缺乏症高发地区的学龄儿童的线性生长、身体成分或青春期发育。
设计、地点和参与者:这是一项双盲、安慰剂对照随机临床试验的二次分析,于 2016 年 6 月至 2019 年 6 月在蒙古乌兰巴托的 18 所小学进行。参加研究的学龄儿童(基线时 6 至 13 岁)。排除标准包括 QuantiFERON-TB Gold 管内检测结果阳性、与维生素 D 代谢改变相关的病症或药物、使用维生素 D 补充剂、佝偻病迹象或计划在 4 年内离开乌兰巴托。在受邀参加研究的 11475 名儿童中,有 9814 名接受了 QFT 检测,8851 名检测结果为阴性的儿童被纳入研究。安慰剂组中除 1 名参与者外,其余均完成了随访并纳入本次分析。数据于 2021 年 11 月至 2022 年 2 月进行分析。
每周口服维生素 D3,剂量为 14000IU(n=4418)或安慰剂(n=4433),持续 3 年。
身高年龄 z 评分、体重指数年龄 z 评分和腰高比;体脂肪百分比、体脂肪量和体脂肪量;青春期发育的 Tanner 评分。
在 8851 名参与者中,有 4366 名(49.3%)为女性,8165 名(92.2%)为喀尔喀人;平均(SD)年龄为 9.4(1.6)岁。共有 8453 名参与者(95.5%)在基线时维生素 D 缺乏,随机分配至维生素 D 组和安慰剂组的参与者在研究结束时 25(OH)D 浓度分别为 31.0ng/mL 和 10.7ng/mL(平均差异,20.3;95%CI;19.9-20.6)。然而,维生素 D 补充剂对身高年龄、体重指数年龄、腰高比、体脂肪百分比、体脂肪量、体脂肪量或 Tanner 评分均无影响,无论总体还是按基线 25(OH)D 浓度<10ng/mL 与≥10ng/mL、估计钙摄入量<500mg/d 与≥500mg/d 或男性与女性进行分层。
在本研究中,维生素 D 基线水平较低的学龄儿童中,每周口服 14000IU 维生素 D3 3 年有效提高了 25(OH)D 浓度,但对生长、身体成分或青春期发育没有影响。
ClinicalTrials.gov 标识符:NCT02276755。